Press release: Umeå, 22 December 2021. Extra general meeting in Lipum AB (publ), corporate identity number 556813-5999 (the "Company") was held on 22 December 2021 in Umeå by postal voting, whereby the shareholders, in accordance with the notice, primarily resolved on the following matters.

Decision on the introduction of incentive programs for employees and consultants

The meeting resolved that the program shall consist of a maximum of 72,500 warrants, each of which entitles the holder to subscribe for one share in the Company.

Decision on the introduction of an incentive program for board members

The meeting resolved that the program shall consist of a total of a maximum of 52,500 warrants, each of which entitles the holder to subscribe for one share in the Company.

All resolutions at the extra general meeting were resolved unanimously. Minutes (in Swedish) are available on Lipum's website.

For further information, please contact:  
Einar Pontén, CEO 
E-post:       einar.ponten@lipum.se 
Mobile:        +46 70 578 34 95 
Web:    www.lipum.se

Lipum AB 

The Board of Directors 

About Lipum 
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: ca@gwkapital.se,phone: +46 8 503 000 50.